**Name of Journal: *World Journal of Transplantation***

**ESPS Manuscript NO: 21147**

**Manuscript Type: REVIEW**

**Induced pluripotent stem cells for modeling neurological disorders**

Russo FB *et al*. Modeling neurological diseases

**Fabiele Baldino Russo, Fernanda Rodrigues Cugola, Isabella Rodrigues Fernandes, Graciela Conceição Pignatari, Patrícia Cristina Baleeiro Beltrão-Braga**

**Fabiele Baldino Russo, Isabella Rodrigues Fernandes, Fernanda Rodrigues Cugola, Graciela Conceição Pignatari and Patrícia Cristina Baleeriro Beltrão Braga,** Stem Cell Lab, Department of Surgery, School of Veterinary Medicine, University of São Paulo, São Paulo 05508-270, Brazil

**Patrícia Cristina Baleeiro Beltrão Braga**, Center for Cellular and Molecular Therapy (NETCEM), School of Medicine, University of São Paulo, São Paulo 01246-903, Brazil

**Patrícia Cristina Baleeiro Beltrão Braga**, Obstetrics Department, School of Arts, Sciences and Humanities, University of São Paulo, São Paulo 03828-100, Brazil

**Author contributions:** All authors contributed to this manuscript, collecting data and writing.

**Conflict-of-interest statement:** All authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Patrícia Cristina Baleeiro Beltrão Braga**, **PhD, Assistant Professor**, Center for Cellular and Molecular Therapy (NETCEM), School of Medicine, University of São Paulo, 87 Prof. Dr. Orlando Marques de Paiva Av., São Paulo 01246-903, Brazil. [patriciacbbbraga@usp.br](mailto:patriciacbbbraga@usp.br)

**Telephone:** +55-11-30911417

**Fax**: +55-11-30917690

**Received:** June 29, 2015

**Peer-review started:** July 3, 2015

**First decision:** July 30, 2015

**Revised:** August 23, 2015

**Accepted:** September 25, 2015

**Article in press:**

**Published online:**

**Abstract**

Several diseases have been successfully modeled since the development of induced pluripotent stem cell (iPSC) technology in 2006. Since then, methods for increased reprogramming efficiency and cell culture maintenance have been optimized and many protocols for differentiating stem cell lines have been successfully developed, allowing the generation of several cellular subtypes *in vitro*. Gene editing technologies have also greatly advanced lately, enhancing disease-specific phenotypes by creating isogenic cell lines, allowing mutations to be corrected in affected samples or inserted in control lines. Neurological disorders have benefited the most from iPSC-disease modeling for its capability for generating disease-relevant cell types *in vitro* from the central nervous system, such as neurons and glial cells, only available from post-mordem samples otherwise. Patient-specific iPSC-derived neural cells can recapitulate the phenotypes of these diseases and therefore, considerably enrich our understanding of pathogenesis, disease mechanism and facilitate the development of drug screening platforms for novel therapeutic targets. Here, we review the accomplishments and the current progress in human neurological disorders by using iPSC modeling for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Schizophrenia and Autism Spectrum Disorders, which include Timothy syndrome, Fragile X syndrome, Angelman syndrome, Prader-Willi syndrome, Phelan-McDermid, Rett syndrome as well as Nonsyndromic Autism.

**Key words**: Neurological disorders; Induced pluripotent stem cells; Induced pluripotent stem cell; Disease modeling; Human neurons; Drug screening

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Several diseases have been successfully modeled using induced pluripotent stem cell (iPSC) technology. Neurological disorders are frequent targets of iPSC-disease modeling for its ability to generate *in vitro* disease-relevant cell types from the central nervous system, such as neurons and glial cells. Patient-specific iPSC-derived neural cells can recapitulate the phenotypes of these diseases, unveiling mechanisms and providing drug screening platforms for novel therapeutic targets. Here, we review the accomplishments and the current progress achieved in human neurological disorders by using iPSC modeling for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Schizophrenia and Autism Spectrum Disorders.

Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrão-Braga PCB. Induced pluripotent stem cells for modeling neurological disorders. *World J Transplant* 2015; In press

**INTRODUCTION**

Induced pluripotent stem cell (iPSC) technology was first described in 2006 by Takahashi and Yamanaka, when murine fibroblast cells were reprogrammed to a pluripotent stage[1], with the protocol being successfully applied to human fibroblast cells on the following year by the same group[2]. Since then, iPSCs have been greatly used by many laboratories for pathobiology studies, discovery of disease mechanisms and potential drug-screening platforms[3,4].

Neurological diseases have benefited enormously from iPSC technology for it allowing *in vitro* production of human cells that wouldn’t be accessible otherwise, such as the brain, and protocols for generating well-defined neural cell types are already available, being used by several research groups. In our laboratory, the protocol described by Marchetto and colleagues for generating cortical neurons has been successfully reproduced[5]. The steps for neuron generation are represented in Figure 1.

In this review, we introduce an overview of the use of iPSC technology for Alzheimer's disease, Parkinson’s disease, Huntington disease, Spinal muscular atrophy, Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Autism (syndromic and nonsyndromic) and Schizoprhenia as well as its application as a drug screening platform and potential therapeutic application.

***Alzheimer’s disease***

Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease affecting the aging population in which patients display gradual memory loss and cognitive impairment. AD can be classified as sporadic late onset (S-AD), which mostly occur after the age of 65 and accounts for 95% of the cases, or more rarely familiar early onset (F-AD), developing in patients in as early as their 30 s. Both occurrences present similar clinical features and pathological phenotypes. For familial cases of AD, mutations in amyloid precursor protein (APP), presenilin 1 and 2 (PS1, PS2) were identified[6].

The amyloid hypothesis of AD pathogenesis stems from the accumulation and aggregation of plaques in the brain comprised of β-amyloid (Aβ) peptides and a hyper phosphorylated form of microtubule associated protein Tau (MAPT). Point mutations in PS1 or PS2, which form the major component of the γ-secretase complex, affect the γ-secretase-mediated processing of APP, increasing formation of Aβ42 within the neurons, wielding a toxic effect, obstructing neuronal communication and causing oxidative stress[7-9]. Nevertheless, it has been reported contradictory results in animal models for the role of APP in AD[10] and most drugs candidates in clinical trials have failed, implying that to prevent functional and cognitive decline, aiming Aβ alone may not be enough. Utilizing iPSCs in AD modeling allow to further investigate if the cause of neurodegeneration is due to accumulation of Aβ and provide a new method to relate S-AD pathogenesis and newly identified genetic risk variants[11].

Several groups have already successfully generated AD patient specific iPSC-derived neuron lines, providing a novel strategy to investigating the pathogen pathways of the disease[12-14]. Yagi and colleagues first generated neurons from iPSCs from F-AD patients carrying PS1 or PS2 mutations, which revealed elevated levels of Aβ, thus confirming the amyloid cascade hypothesis[12]. Israel and colleagues generated iPSC from two F-AD patients harboring duplications of the *APP* gene and two S-AD patients and found higher levels of the pathological marker Aβ40, phosphorylated tau (Thr231) and active glycogen synthase kinase-3β (GSK-3β), when compared to matched control iPSCs, in both F-AD patients and one S-AD patient[14]. Further treatment of the cells with β-secretase inhibitor improved levels of Thr231 and GSK-23, indicating an APP-tau relationship. Although only one of the S-AD lines recapitulated F-AD phenotype (APP duplication), the autosomal-dominant mechanism forms of F-AD may provide insight into the pathogenesis of S-AD in future studies. Nevertheless, larger numbers of samples will be required in order to fully access their genetic heterogeneity.

Additional studies approaching drug and toxicity screenings in AD, used neuronal cells-iPSC derived, positive for forebrain markers and able to secrete functional proteins involved in Aβ, as well as APP, β-secretase and γ-secretase[15]. After treatment with β- and γ-secretase inhibitors, differences in susceptibility to drugs between the early and late differentiation stages of the cells were reported. Another group used AD iPSC-derived neurons to test for molecules effective against Aβ42 toxicity and revealed that cyclin-dependent kinase 2 (Cdk2) inhibitor block Aβ toxicity in the differentiated neural cells[16]. Both studies show the potential that iPSC technology represents in modeling AD and allow to examine patient-specific phenotypes *in vitro* reflecting the familial and sporadic forms of Alzheimer’s disease, as they are often indistinguishable clinically.

***Parkinson’s disease***

Parkinson’s disease (PD) is the second most common neurodegenerative disease, behind only to Alzheimer’s disease, and it’s characterized by progressive loss of dopaminergic neurons (DA) from substantia nigra. Patients display progressive motor dysfunction, such as tremor, rigidity, akinesia and bradykinesia. Most cases of PD are sporadic, but about 20% of patients display familial monogenic forms of the disease[17]. Pathological hallmarks of PD are characterized by presence of Lewy bodies composed of alpha-synuclei (α-syn) protein beyond the nigra and the cortex.

The first dominantly inherited familial PD genetic cause identified was linked to alpha synuclei encoded by the SNCA gene[18], with four mutations currently described[19-22], which causes a misfolding of the protein leading to neuronal dysfunction. Alpha-synuclei is believed to participate in pre-synaptic functions of DA neurons, though the complete actual role of α-SYN is still unknown. DA neurons were generated from iPSCs from a family who carried a triplication of the SNCA locus and expressed double the amount of α-SYN when compared to healthy controls[18]. Further analysis on iPSC-derived DA neurons from the same family, showed increases in mRNA for genes associated with oxidative stress, such as haemoxygenase 2 (HMOX2) and monoamine oxidase (MAO), and when these neurons were exposed to hydrogen peroxide, increased activation of caspase-3 was detected, suggesting that high levels of α-SYN may present a toxic effect on DA neurons under stress[23].

Another mutation, in *A52T SNCA* gene, was corrected using zinc finger nuclease (ZFN) technology, both in mutated and control iPSC lines in order to correct the mutation and generate isogenic control lines, respectively. However, the iPSC-derived DA neurons generated were not evaluated, but authors showed the proof of principle that isogenic cell lines are important to evaluate consequences of mutated genes[24].

Two other dominant forms later characterized were linked to mutations in glucocerebrosidase (GBA) and leucine rich repeat kinase 2 (*LRRK2*) genes[25-27]. Mutations in *LRRK2* gene, usually G2019S, are the most common cause of familial PD, being intensively investigated with use of iPSC technology[28-32]. Increased expression of alpha-synuclein in iPSC-derived DA neurons from LRRK2-mutant lines was found[28], fact observed by other studies[29,32], suggesting a connection between these risk genes, as well as increased expression of oxidative stress genes and increased activation of caspase-3 after treatment with H2O2. Another study used ZFN technology in G2019S-iPSC and health control iPSC lines to correct and add the G2019S mutation, respectively, observed the reversal of the pathogenic phenotype associated with the G2019S mutations[33].

There are three early onset autosomal recessive forms of PD, caused by mutations in Parkin (PARK2), PTEN induced kinase 1 (PINK1) and DJ1 (PARK7)[34-36]. Parkin is believed to mediate mitophagy on a system dependent on PINK1 and account for most cases of early-onset PD[37]. Studies done by different groups in PD iPSC-derived neurons found impaired Parkin recruitment after mitochondria depolarization and observed indications that mutations in PARK2 may predispose neurons to oxidative stress, though details of the exact phenotype remains unclear[38-41].

***Huntington’s disease***

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease, affecting approximately 1:10000 persons[42]. Mutations in the *huntingtin* gene (HTT) lead to poliglutamine repetitions (CAG), causing psychiatric and physiologic alterations[43,44]. Patients with HD display progressive motor and cognitive impairments, change in personality, loss of function along with a decrease in number of neurons, among other symptoms[44,45].

The development of iPSC technology applied to human cells[2] helped elucidate the mechanisms of several devastating neurologic diseases, as HD. Cells from HD patients were first reprogrammed into iPSC in 2010[46], and alterations in electrophysiology, cell metabolism, adherence and toxicity were reported. Expansion of a CAG repeat alters the transport and release of BDFN and increases glutamate receptors, producing toxicity and oxidative stress in neuron and glial cells[44,46,47]. HD iPSC-derived astrocytes displayed 34% more vacuoles when compared to healthy control astrocyte cell lines[42] and on HDN177-82Q mice model, it was observed that mutation in gene HTT causes severe neurological phenotypes and dysfunction in glia cells[48].

Another study created genetically corrected HD iPSCs lines and further differentiated them into neural stem cells (NSC), which displayed normalized pathogenic TGF-β and cadherin signaling pathways. When these genetically corrected NSCs were transplanted into a transgenic HD mice model, it was observed that they were able to populate the striatum after a two week post-transplantation period, uncovering advancements for a potential stem cell replacement therapy[49].

***Spinal muscular atrophy***

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease caused by mutations in survival of motor neuron gene (*SMN-1*), characterized by a selective and progressive loss of lower motor neurons resulting in degeneration of motor neurons in the spinal cord and muscular atrophy on limbs and trunk[50-52].

In order to uncover what is really happening from an inside perspective of the patient’s body, iPSC technology can be used to elucidade this disease mechanism[53]. This was first demonstrated by Ebert and colleagues[50] using fibroblast cells from SMA patients, which were reprogrammed into iPSCs by lentiviral infection carrying Oct4, Sox2, Nanog and Lin28 factors. When these iPSCs were further differentiated into motor neurons, it was observed they displayed smaller soma size and incomplete synapses formation. Valproic acid (1mM) and Tobramycin (320 uM) drugs, both previously described in the treatment of SMA patients[54], were tested and appeared to increase the production of SMN protein in iPSC-derived motor neurons. Valproic acid and anti-sense oligo treatment help improve defects in AChR clustering, increasing levels of SMN transcripts[55].

The neuronal differentiation of SMA iPSCs show reduced capacity to produce motor neurons[51], therefore, applying gene correcting technology may aid in overcoming these methodological shortcomings. The correction of *SMN* gene, using single-stranded oligonucleotide, was shown to restore the *SMN* gene profile in neurons derived from SMA-iPSC, converting SMN2 in SMN1[56]. Furthermore, these corrected-gene cells were transplantated in SMA rat models, improving the animals’ disease phenotype and life extension. The possibility of generating genetically corrected, patient-specific SMA-iPSC derived motor neurons and the positive results observed from transplantation in this study, open the path for therapeutic application of autologous cell therapy for SMA patients[57].

***Amyotrophic lateral sclerosis***

Amyotrophic lateral sclerosis (ALS) is a late adult onset neurodegenerative disease characterized by a progressive degeneration of motor neurons in the cortex, brainstem and bone marrow[58,59]. ALS is a devastating disease; the loss of motor neurons and muscle atrophy confine patients to a wheelchair very rapidly, followed by respiratory failure. The cause of ALS is not yet elucidated, however, mutations in genes *SOD1, C9orf72, TDP-43, FUS / TLS*, angiogenin, Matrin 3[60-65] and others, have been associated with ALS. Moreover, familial inheritance accounts for about 10% of the cases of patients diagnosed with ALS[65].

Several studies using reprogrammed cells generated from patients of different diseases have been described since 2008[66,67] and they have and still contribute to the understanding, from a physiological point of view to prospective treatments, of these diseases. The first group to generate ALS-derived iPSCs reprogrammed fibroblast cells and further differentiated them into motor neuron cells, opening the path to studies on ALS pathogenesis, yieldin a model for testing novel compounds and for autologous cell replacement therapy[67].

iPSC-derived motor neuron cells have been shown to be physiologically active *in vitro* after reprogramming[68,69] and were immunopositive for ISL+ (motor neuron marker)[68], MNX1 (motor neuron and pancreas homebox protein 1)[69] and also, displaying a phenotype for cholinergic transmitters, positive for ChAT (acetylcholine marker)[68,69].

Neural progenitor cells (NPC), which can be generated from iPSC, have become a promising source for cell therapy for ALS. These cells have been transplanted in the lumbar spinal cord in ALS mice models, further differentiated into neurons and astrocytes, and were shown to be able to improve the quality and lifespan of these mice[70,71].

Recently, the world has drawn attention to the ALS “Ice bucket” campaign[72], gaining scientific research strength and raising public awareness about the disease. ALS iPSC research can contribute as a platform to developing new therapeutics, clinical application with cell and gene therapies, enabling new opportunities for future patients’ treatments.

***Duchenne muscular dystrophy***

Mutations in the dystrophin gene, located on X chromosome in region p21, lead to dysfunctions in the production of dystrophin, resulting in a misfolded protein. Partial expression or total loss of the dystrophin cause weakness and progressive degeneration of skeletal muscles, reported symptoms of the Duchenne Muscular Dystrophy (DMD), whose prevalence is high, affecting approximately 1 in 3300 males[73].

Dystrophin provides support between the actin filaments and cell membrane (sarcolemma) in muscle cells but may also be found in other cellular types, such as in the retina, liver, heart, brain, *etc.*[74]. Moreover, dystrophin appears to act in the Central Nervous System (CNS). Some studies have reported that DMD patients have difficulties in tests requiring attention and verbal repetition, as well as deficits in speech processing and reading, suggesting DMD may be a cerebellar disorder[75,76]. Approximately one third of DMD patients show cognitive impairment[77,78], in which the mutations in the dystrophin gene seem to alter the efficiency of the brain-cerebellum path, as well as change the neuronal and brain architecture, leading to cognitive deficits in these patients[75-77].

Modeling Duchenne Muscular Dystrophy *in vitro* will help disclose the neurological mechanism of this disease and even allow to correct the dystrophin deficit in the muscle. To date, cardiomyoblast cells, muscle cells and neurons have been generated from iPSC cells[79-82]. The first group to reprogram cells from DMD patients was Park et al. in 2008[66], followed by other groups modeling DMD *in vitro* and whose primary objective was to correct the dystrophin in muscle cells. Furthermore, studies applying human artificial chromosome, CRISPR / Cas9 and TALEN technologies[82-84] reported to have restored the expression of dystrophin, observed *in vitro* and *in vivo*.

Neuromuscular diseases like DMD have been the focus of iPSC modeling disease studies, which allow the creation of platforms to correct genetic mutations as well as for drug discovery, opening doors to personalized medicine.

**AUTISM**

Autism spectrum disorder (ASD) is a group of complex neurodevelopmental disorders, affecting 1% of the world’s population, characterized by qualitative communication impairment, atypical social interaction and restricted and repetitive patterns of behavior[85-87]. Autism can be categorized in syndromic and nonsyndromic types. Syndromic autism is definied by an identified neurological disorder, harboring a set of associated phenotypes, where the genetic cause is known and gene mutation is identified. Syndromic forms of ASD are Timothy syndrome, Fragile X syndrome, Angelman syndrome, Prader-Willi syndrome, Phelan-McDermid and Rett syndrome[5,88-91]. Studies using iPSC technology have already been reported for all of these diseases. Nonsyndromic autism, or simple called ASD, is a group of comorbidities whose genetic cause is not well defined yet, although some genes involved are known, and accounts for the majority of autism cases.

***Timothy syndrome***

Timothy Syndrome (TS) is a rare genetic disorder caused by *de novo* missense mutation in the CACNA1C gene[92,93] and it is associated with developmental delay and autism[92]. This gene encodes the α-subunit of the voltage-gated calcium channel Cav1.2. This channel plays a central role in regulating and signaling network that is essential for neuronal function[94-96].

Cortical neuronal precursor cells and neurons were first differentiated from iPSCs generated from patients with Timothy syndrome by Pasca and colleagues. Intracellular calcium (Ca2+) signals were examined in these cells and a significant increase in TS neurons was observed[88]. Furthermore, TS patient specific-iPSCs were generated to study the effects of the mutation on dendritic arbors. The results found in these cells were then compared to a TS rodent model and revealed an aberrant activity-dependent dendritic retraction in both human derived neurons and animal neurons[97].

Mutations in ion channel genes have been associated with cardiac arrhythmias and TS, but the pathophysiological process is little known. TS iPSC-derived cardiomyocyte cells displayed an erratic and slow contraction behaviour when compared to healthy controls, as well as abnormal calcium handling and irregular and prolonged action potential patterns[98].

***Fragile X syndrome***

Fragile X syndrome (FXS) is the most common form of syndromic ASD and mental retardation[89]. FXS is caused by loss of expression of the fragile X mental retardation gene 1 (*FMR1*) located in the X-chromosome, where an expanded CGG repeats in the 5'-untranslated region of the *FMR1* gene is present[89,99]. FSX has no cure and patients display developmental impairment, learning and cognitive disabilities, as well as physical and behavioral phenotypes such as [stereotypic movements](http://en.wikipedia.org/wiki/Stereotypy)[100,101].

*FMR1* gene is associated with synaptogenesis and the FMRP protein can be detected at synapses and dendritic spines[102]. The first FXS iPSC model was derived from fibroblasts and described by Urbach and colleagues. Their findings reported the *FMR1* gene remained inactive and highlighted crucial differences between ES and iPS cells[89]. Another study reported variable levels of FMR1 silencing and expression in multiple FXS iPSC lines. Furthermore, these lines showed reduced FRM1 expression during neuronal differentiation[99].

FMRP expression works as an indicator for drug discovery for FXS. In a recent drug screening study, 6 compounds were shown to increase *FMR1* gene expression in neural stem cells differentiated from a FXS iPSC line. Despite none of these compounds resulted in clinically relevant levels of FMR1, these findings support the idea this assay can be used as a drug screening platform for FXS[101].

Another study showed that iPSC-derived neurons from FXS patients displayed fewer synaptic protein levels and synapses, reduced neurite length and abnormal functionality, with increased calcium transients[103]. Reduced neurite was also observed in forebrain neurons derived from FXS iPSCs[104].

***Angelman syndrome and Prader-Willi syndrome***

Angelman syndrome (AS) and Prader–Willi syndrome (PWS) are neurodevelopmental disorders associated with autism caused by deletions in chromosome 15q11–q13[105]. AS is caused by reduced expression of the ubiquitin-protein ligase E3A gene (*UBE3A*) of the maternal chromosome[106-108] whereas PWS occurs by the same deletion on the paternally inherited allele[109]. They both share same behavioral and neurological phenotypes. However, cognitive and neurologic impairments are more severe in AS, including seizures, while behavioral problems are more severe in PWS[109].

The first study to model AS and PWS using iPSC-derived from patients was done by Chamberlain and colleagues. Although the authors found no phenotypic differences between AS and control neurons, they observed the UBE3A imprinting occurred during neuronal differentiation in AS cells[105].

Recently, iPSCs from a PWS patient with an atypical microdeletion on paternal chromosome 15q11–q13 were generated[90], revealing they expressed UBE3A-ATS, typically restricted to neurons as is, consequently, the imprinted expression of UBE3A observed in these iPSCs, as well[90].

Another study generated iPSCs from patients with duplications of chromosome 15q11-q13.1 (Dup15q syndrome) and were further differentiated into functional neurons. Gene expression analysis was performed and compared to AS neurons, revealing they shared common neuronal pathways disrupted in both Angelman and Dup15q syndromes[110].

***Phelan-McDermid syndrome***

Phelan-McDermid syndrome (PMDS) is a rare disorder associated with deletions in chromosome 22q13[91,111]. PMDS is a monogenic form of ASD with a frequency of at least 0.5% of ASD cases and is resulted by deletions in SHANK3 (SH3 and multiple ankyrin repeat domains 3)[112]. This gene plays an important role in synaptic function and is involved in the organization of postsynaptic density[113,114]. PMDS patients display some autistic features as severe language delay and intellectual disability[115]. Animal models for ASD carrying Shank3 mutations display synaptic dysfunction, abnormal social behavior, repetitive and communication behavior patterns and deficient learning and memory[116].

Recently, Shcheglovitov and colleagues generated iPSC-derived neurons from individuals with PMDS carrying large 22q13 deletions that included SHANK3[117]. These neurons displayed fewer synapses and altered electrophysiology. The group reported that excitatory synaptic transmission in PMDS neurons can be corrected by restoring SHANK3 expression or by treating neurons with insulin-like growth factor 1 (IGF1)[117].

***Rett Syndrome***

Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by mutations in the X-linked gene methyl CpG-binding protein 2 (MeCP2)[5,118]. RTT syndrome affects more females with an incidence of 1 in 10000[118]. Rett patients display a normal development until 18 mo of age, but thereafter, progressive neurological abnormalities begin to emerge[119]. Neurologic pathologies as autistic behavior, stereotypies, loss of speech, microcephaly, seizures and hypotonia have been described in RTT patients[120].

Several studies utilizing RTT-derived iPSC have been published in the past years. The first RTT-derived iPSC lines were generated by the Ellis group[121], however, the first group to make use of iPSC for disease modeling of RTT syndrome was by Marchetto and colleagues[5]. In this work, iPSC-derived neurons from four different RTT patients were generated. Neuronal phenotypes displayed reduced dendritic spine density, smaller soma size, altered electrophysiology, alterations in Ca2+ influx and fewer synapses. Furthermore, insulin-like growth factor 1 (IGF-1) was able to rescue the synaptic defects in these neurons after treatment[5]. Reduced soma and nuclear size phenotypes from RTT iPSC-derived neurons were also observed by another group[122] as well as defects in neuronal maturation[123].

IPSC-derived neurons from heterozygous Mecp2308 mice showed defects in glutamatergic synaptic transmission and generation of action potentials and decreased action potential amplitude. These phenotypes were observed in neurons derived from WT and hemizygous mutant iPSC lines, indicating that these deficits are caused by MeCP2 deficiency[124].

The first isoform-patient specific iPSC model of RTT was reported by Dijuric and colleagues. iPSC-derived neurons from RTTe1 maintain an inactive X-chromosome and express only the mutant allele. Mutant neurons exhibited reduced dendritic complexity, decreased soma size and cell capacitance[125].

Recently, astrocytes derived from RTT iPSCs were generated by William and colleagues[126]. The group demonstrated that these mutant astrocytes can affect directly the neurons and induce abnormalities. IGF-1 and GPE (an IGF-1 peptide) can partially rescue the morphological defects[126].

RTT Syndrome has become a popular target for iPSC studies and this technology has greatly contributed to a better understanding of the disease.

***Nonsyndromic Autism***

Research on syndromic autism provides us with data that can contribute to the understanding of nonsyndromic autism cases, where the genetic causes are still unknown. Furthermore, animal models provide valuable information on ASD, with recent studies showing similar synaptic phenotypes in nonsyndromic and syndromic mouse models of autisms[127].

The first iPSC model of nonsyndromic autism was recently generated by Griesi and colleagues[128]. In this study, the group investigated the molecular and cellular phenotypes in iPSC-derived neurons from an ASD individual carrying a mutation in the *TRPC6* gene, which encodes for protein channel Transient Receptor Potential Canonical 6. TRPC6 protein operates in a calcium channel in the brain, controlling the functioning of neurons, in particular neuronal synapses[128]. *In vitro* analysis revealed that this mutation leads to a reduction of synapses and morphological changes in mouse neurons. These data showed phenotypes in common with findings from syndromic autism[5,88,89,105,117], where the studies demonstrated neuronal abnormalities such as altered morphology and synaptic deficits. The group was also able to rescue some of the neuronal abnormalities using candidate drugs as, IGF-1 and hyperforin. This study brings valuable information to the understanding of autism disorder, despite this mutation occurs in less than 1% of patients with ASD and the genetics of autism is quite complex and involves several genes[129]. This is the first study to model nonsyndromic autism using iPSC, however more studies should be done to better unveil this disorder and access future therapy applications.

***Schizophrenia***

Schizophrenia (SCZD), like nonsyndromic autism, is a complex neurological disorder where the genetic causes are still unclear, affecting a large number of individuals (1.1% of the world’s population)[130,131]. It is considered to stem from a polygenic basis, with an estimated heritability of approximately 80%[130,132,133], and genetic and epigenetic processes underlying the disease, as it was observed in a discordant monozygotic twin study[133]. Moreover, environmental stressors like drug use, being cannabis the most frequently studied, birth complications, maternal immune response, among others, may contibute to SCZD[134-137].

People with SCZD have a lower life expectancy average, mostly to increased health problems and higher suicide rate, and individuals may experience symptoms like hallucinations, delusions, abnormal social behavior (inability to speak, express emotions or find pleasure) and cognitive impairment (deficits in attention, memory and planning)[131,132].

The very first study published with iPSC derived from SCZD patients did not produce neurons[138]. A different group published that same year a study using iPSC technology for SCZD modeling. In this study, iPSC-derived neurons were characterized and revealed defects in neuronal connectivity, reduced outgrowth from soma, reduced PSD95 dendritic protein levels and some altered gene expression. Furthermore, phenotypes in SCZD neurons were ameliorated after treatment with Loxapine, an antipsychotic drug[139].

Another work using SCDZ iPSC-derived neurons carrying 22q11 deletions observed a high L1 copy number in these cells, confirmed by neuronal genome analysis, validating the use of iPSC technology in the study of SCZD condition[140]. Notwithstanding these evidences and taking into consideration SCZD heterogeneity, more studies should be carried out bearing in mind the use of more homogeneous populations, by selecting subjects with rare genetic variants or with similar clinical manifestations[141].

***Perspectives***

The path for disease treatment and prevention is through the unveiling of pathogenesis and physiological mechanisms that ultimately result in the phenotypic symptoms of diseases. Analysis of live and post-mortem samples, as well as animal models, are great sources for disease study outlines. Despite the importance and relevance of the use of animal models in research, they sometimes are inadequate to fully recapitulate the pathology as it is in humans, and consequently, many drug candidates that once showed to be therapeutically promising in animal models, failed in clinical trials in humans[142].

The development of iPSC technology has come to aid to fill in the gap between pathogenesis and *in vivo* phenotypes. Since the first human iPSC line was established, this methodology has been used by many laboratories for the study of neurological and psychiatric disorders.

Neuroscience research has taken a significant step with iPSC disease modeling. The possibility of generating patient-specific cell lines and differentiating them into various cellular subtypes *in vitro*, allow the creation of future personalized therapeutical treatments. This procedure is represented in Figure 2.

Although iPSC technology holds great potential for disease modeling and research, it is still in its initial phase. This promising technology provides a useful platform for a better understanding of neurological diseases mechanisms, drug discovery and future therapeutical applications.

**ACKNOWLEDGMENTS**

Our acknowledgement is to Lenon Della Rovere for figure design support.

**REFERENCES**

1 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

2 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

3 **Grieshammer U**, Shepard KA. Proceedings: consideration of genetics in the design of induced pluripotent stem cell-based models of complex disease. *Stem Cells Transl Med* 2014; **3**: 1253-1258 [PMID: 25359995 DOI: 10.5966/sctm.2014-0191]

4 **Santostefano KE**, Hamazaki T, Biel NM, Jin S, Umezawa A, Terada N. A practical guide to induced pluripotent stem cell research using patient samples. *Lab Invest* 2015; **95**: 4-13 [PMID: 25089770 DOI: 10.1038/labinvest.2014.104]

5 **Marchetto MC**, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* 2010; **143**: 527-539 [PMID: 21074045 DOI: 10.1016/j.cell.2010.10.016]

6 **St George-Hyslop PH**. Genetic factors in the genesis of Alzheimer's disease. *Ann N Y Acad Sci* 2000; **924**: 1-7 [PMID: 11193785 DOI: 10.1111/j.1749-6632.2000.tb05552.x]

7 **Zhang YW**, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. *Mol Brain* 2011; **4**: 3 [PMID: 21214928 DOI: 10.1186/1756-6606-4-3]

8 **Hardy JA**, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992; **256**: 184-185 [PMID: 1566067 DOI: 10.1126/science.1566067]

9 **Wolfe MS**. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. *EMBO Rep* 2007; **8**: 136-140 [PMID: 17268504 DOI: 10.1038/sj.embor.7400896]

10 **Khandekar N**, Lie KH, Sachdev PS, Sidhu KS. Amyloid precursor proteins, neural differentiation of pluripotent stem cells and its relevance to Alzheimer's disease. *Stem Cells Dev* 2012; **21**: 997-1006 [PMID: 22122714 DOI: 10.1089/scd.2011.0564]

11 **Bettens K**, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. *Lancet Neurol* 2013; **12**: 92-104 [PMID: 23237904 DOI: 10.1016/S1474-4422(12)70259-4]

12 **Yagi T**, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet* 2011; **20**: 4530-4539 [PMID: 21900357 DOI: 10.1093/hmg/ddr394]

13 **Kondo T**, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. *Cell Stem Cell* 2013; **12**: 487-496 [PMID: 23434393 DOI: 10.1016/j.stem.2013.01.009]

14 **Israel MA**, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 2012; **482**: 216-220 [PMID: 22278060 DOI: 10.1038/nature10821]

15 **Yahata N**, Asai M, Kitaoka S, Takahashi K, Asaka I, Hioki H, Kaneko T, Maruyama K, Saido TC, Nakahata T, Asada T, Yamanaka S, Iwata N, Inoue H. Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. *PLoS One* 2011; **6**: e25788 [PMID: 21984949 DOI: 10.1371/journal.pone.0025788]

16 **Xu X**, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, Sun M, Nuwaysir E, Fan G, Zhao J, Lei L, Zhong Z. Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. *Stem Cell Res* 2013; **10**: 213-227 [PMID: 23305945 DOI: 10.1016/j.scr.2012.11.005]

17 **Lesage S**, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Hum Mol Genet* 2009; **18**: R48-R59 [PMID: 19297401 DOI: 10.1093/hmg/ddp012]

18 **Singleton AB**, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 2003; **302**: 841 [PMID: 14593171 DOI: 10.1126/science.1090278]

19 **Polymeropoulos MH**, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 1997; **276**: 2045-2047 [PMID: 9197268 DOI: 10.1126/science.276.5321.2045]

20 **Krüger R**, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet* 1998; **18**: 106-108 [PMID: 9462735 DOI: 10.1038/ng0298-106]

21 **Zarranz JJ**, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol* 2004; **55**: 164-173 [PMID: 14755719 DOI: 10.1002/ana.10795]

22 **Appel-Cresswell S**, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ. Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. *Mov Disord* 2013; **28**: 811-813 [PMID: 23457019 DOI: 10.1002/mds.25421]

23 **Byers B**, Cord B, Nguyen HN, Schüle B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. *PLoS One* 2011; **6**: e26159 [PMID: 22110584 DOI: 10.1371/journal.pone.0026159]

24 **Soldner F**, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. *Cell* 2011; **146**: 318-331 [PMID: 21757228 DOI: 10.1016/j.cell.2011.06.019]

25 **Aharon-Peretz J**, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. *N Engl J Med* 2004; **351**: 1972-1977 [PMID: 15525722 DOI: 10.1056/NEJMoa033277]

26 **Neumann J**, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. *Brain* 2009; **132**: 1783-1794 [PMID: 19286695 DOI: 10.1093/brain/awp044]

27 **Zimprich A**, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 2004; **44**: 601-607 [PMID: 15541309 DOI: 10.1016/ j.neuron.2004.11.005]

28 **Nguyen HN**, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schüle B, Dolmetsch RE, Langston W, Palmer TD, Pera RR. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* 2011; **8**: 267-280 [PMID: 21362567 DOI: 10.1016/j.stem.2011.01.013]

29 **Sánchez-Danés A**, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. *EMBO Mol Med* 2012; **4**: 380-395 [PMID: 22407749 DOI: 10.1002/emmm.201200215]

30 **Cooper O**, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Sci Transl Med* 2012; **4**: 141ra90 [PMID: 22764206 DOI: 10.1126/scitranslmed.3003985]

31 **Liu GH**, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J, Esteban CR, Sancho-Martinez I, Izpisua Belmonte JC. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. *Nature* 2012; **491**: 603-607 [PMID: 23075850 DOI: 10.1038/nature11557]

32 **Orenstein SJ**, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Raya A, Sulzer D, Cuervo AM. Interplay of LRRK2 with chaperone-mediated autophagy. *Nat Neurosci* 2013; **16**: 394-406 [PMID: 23455607 DOI: 10.1038/nn.3350]

33 **Reinhardt P**, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. *Cell Stem Cell* 2013; **12**: 354-367 [PMID: 23472874 DOI: 10.1016/j.stem.2013.01.008]

34 **Bonifati V**, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 2003; **299**: 256-259 [PMID: 12446870 DOI: 10.1126/science.1077209]

35 **Kitada T**, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 1998; **392**: 605-608 [PMID: 9560156 DOI: 10.1038/33416]

36 **Valente EM**, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 2004; **304**: 1158-1160 [PMID: 15087508 DOI: 10.1126/science.1096284]

37 **Clark IE**, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* 2006; **441**: 1162-1166 [PMID: 16672981 DOI: 10.1038/nature04779]

38 **Seibler P**, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J Neurosci* 2011; **31**: 5970-5976 [PMID: 21508222 DOI: 10.1523/JNEUROSCI.4441-10.2011]

39 **Jiang H**, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. *Nat Commun* 2012; **3**: 668 [PMID: 22314364 DOI: 10.1038/ncomms1669]

40 **Imaizumi Y**, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. *Mol Brain* 2012; **5**: 35 [PMID: 23039195 DOI: 10.1186/1756-6606-5-35]

41 **Brundin P**, Strecker RE, Lindvall O, Isacson O, Nilsson OG, Barbin G, Prochiantz A, Forni C, Nieoullon A, Widner H. Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease. *Ann N Y Acad Sci* 1987; **495**: 473-496 [PMID: 3474955 DOI: 10.1111/j.1749-6632.1987.tb23695.x]

42 **Juopperi TA**, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. *Mol Brain* 2012; **5**: 17 [PMID: 22613578 DOI: 10.1186/1756-6606-5-17]

43 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 1993; **72**: 971-983 [PMID: 8458085 DOI: 10.1016/0092-8674(93)90585-E]

44 **Ross CA**, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol* 2011; **10**: 83-98 [PMID: 21163446 DOI: 10.1016/S1474-4422(10)70245-3]

45 **Sawa A**, Tomoda T, Bae BI. Mechanisms of neuronal cell death in Huntington's disease. *Cytogenet Genome Res* 2003; **100**: 287-295 [PMID: 14526190 DOI: 10.1159/000072864]

46 **Zhang N**, An MC, Montoro D, Ellerby LM. Characterization of Human Huntington’s Disease Cell Model from Induced Pluripotent Stem Cells. PLoS Curr 2010; **2**: RRN1193 [PMID: 21037797 DOI: 10.1371/currents.RRN1193]

47 **Shin JY**, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. *J Cell Biol* 2005; **171**: 1001-1012 [PMID: 16365166 DOI: 10.1083/jcb.200508072]

48 **Bradford J**, Shin JY, Roberts M, Wang CE, Sheng G, Li S, Li XJ. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. *J Biol Chem* 2010; **285**: 10653-10661 [PMID: 20145253 DOI: 10.1074/jbc.M109.083287]

49 **An MC**, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. *Cell Stem Cell* 2012; **11**: 253-263 [PMID: 22748967 DOI: 10.1016/j.stem.2012.04.026]

50 **Ebert AD**, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* 2009; **457**: 277-280 [PMID: 19098894 DOI: 10.1038/nature07677]

51 **Chang T**, Zheng W, Tsark W, Bates S, Huang H, Lin RJ, Yee JK. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. *Stem Cells* 2011; **29**: 2090-2093 [PMID: 21956898 DOI: 10.1002/stem.749]

52 **Wu CY**, Whye D, Glazewski L, Choe L, Kerr D, Lee KH, Mason RW, Wang W. Proteomic assessment of a cell model of spinal muscular atrophy. *BMC Neurosci* 2011; **12**: 25 [PMID: 21385431 DOI: 10.1186/1471-2202-12-25]

53 **Saporta MA**, Grskovic M, Dimos JT. Induced pluripotent stem cells in the study of neurological diseases. *Stem Cell Res Ther* 2011; **2**: 37 [PMID: 21936964 DOI: 10.1186/scrt78]

54 **Brichta L**, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. *Hum Mol Genet* 2003; **12**: 2481-2489 [PMID: 12915451 DOI: 10.1093/hmg/ddg256]

55 **Yoshida M**, Kitaoka S, Egawa N, Yamane M, Ikeda R, Tsukita K, Amano N, Watanabe A, Morimoto M, Takahashi J, Hosoi H, Nakahata T, Inoue H, Saito MK. Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. *Stem Cell Reports* 2015; **4**: 561-568 [PMID: 25801509 DOI: 10.1016/j.stemcr.2015.02.010]

56 **Corti S**, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D, Donadoni C, Salani S, Riboldi G, Magri F, Menozzi G, Bonaglia C, Rizzo F, Bresolin N, Comi GP. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. *Sci Transl Med* 2012; **4**: 165ra162 [PMID: 23253609 DOI: 10.1126/scitranslmed.3004108]

57 **Frattini E**, Ruggieri M, Salani S, Faravelli I, Zanetta C, Nizzardo M, Simone C, Magri F, Corti S. Pluripotent stem cell-based models of spinal muscular atrophy. *Mol Cell Neurosci* 2015; **64**: 44-50 [PMID: 25511182 DOI: 10.1016/j.mcn.2014.12.005]

58 **Papadeas ST**, Maragakis NJ. Advances in stem cell research for Amyotrophic Lateral Sclerosis. *Curr Opin Biotechnol* 2009; **20**: 545-551 [PMID: 19819686 DOI: 10.1016/j.copbio.2009.09.003]

59 **Thomsen GM**, Gowing G, Svendsen S, Svendsen CN. The past, present and future of stem cell clinical trials for ALS. *Exp Neurol* 2014; **262** Pt B: 127-137 [PMID: 24613827 DOI: 10.1016/j.expneurol.2014.02.021]

60 **Pasinelli P**, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nat Rev Neurosci* 2006; **7**: 710-723 [PMID: 16924260 DOI: 10.1038/nrn1971]

61 **Da Cruz S**, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. *Curr Opin Neurobiol* 2011; **21**: 904-919 [PMID: 21813273 DOI: 10.1016/j.conb.2011.05.029]

62 **Egawa N**, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Drug screening for ALS using patient-specific induced pluripotent stem cells. *Sci Transl Med* 2012; **4**: 145ra104 [PMID: 22855461 DOI: 10.1126/scitranslmed.3004052]

63 **Padhi AK**, Jayaram B, Gomes J. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations. *Sci Rep* 2013; **3**: 1225 [PMID: 23393617 DOI: 10.1038/srep01225]

64 **Johnson JO**, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chiò A, Traynor BJ. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat Neurosci* 2014; **17**: 664-666 [PMID: 24686783 DOI: 10.1038/nn.3688]

65 **Li Y**, Balasubramanian U, Cohen D, Zhang PW, Mosmiller E, Sattler R, Maragakis NJ, Rothstein JD. A comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cells. *PLoS One* 2015; **10**: e0118266 [PMID: 25760436 DOI: 10.1371/journal.pone.0118266]

66 **Park IH**, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. *Cell* 2008; **134**: 877-886 [PMID: 18691744 DOI: 10.1016/j.cell.2008.07.041]

67 **Dimos JT**, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 2008; **321**: 1218-1221 [PMID: 18669821 DOI: 10.1126/science.1158799]

68 **Boulting GL**, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT, Mikkilineni S, MacDermott AB, Woolf CJ, Henderson CE, Wichterle H, Eggan K. A functionally characterized test set of human induced pluripotent stem cells. *Nat Biotechnol* 2011; **29**: 279-286 [PMID: 21293464 DOI: 10.1038/nbt.1783]

69 **Du ZW**, Chen H, Liu H, Lu J, Qian K, Huang CL, Zhong X, Fan F, Zhang SC. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. *Nat Commun* 2015; **6**: 6626 [PMID: 25806427 DOI: 10.1038/ncomms7626]

70 **Popescu IR**, Nicaise C, Liu S, Bisch G, Knippenberg S, Daubie V, Bohl D, Pochet R. Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. *Stem Cells Transl Med* 2013; **2**: 167-174 [PMID: 23413376 DOI: 10.5966/sctm.2012-0042]

71 **Kondo T**, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, Inoue H. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. *Stem Cell Reports* 2014; **3**: 242-249 [PMID: 25254338 DOI: 10.1016/j.stemcr.2014.05.017]

72 **Vaidya M**. Ice bucket challenge cash may help derisk ALS drug research. *Nat Med* 2014; **20**: 1080 [PMID: 25295924 DOI: 10.1038/nm1014-1080]

73 **Wingeier K**, Giger E, Strozzi S, Kreis R, Joncourt F, Conrad B, Gallati S, Steinlin M. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. *J Clin Neurosci* 2011; **18**: 90-95 [PMID: 21109441 DOI: 10.1016/j.jocn.2010.07.118]

74 **Muntoni F**, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol* 2003; **2**: 731-740 [PMID: 14636778 DOI: 10.1016/S1474-4422(03)00585-4]

75 **Hinton VJ**, Fee RJ, Goldstein EM, De Vivo DC. Verbal and memory skills in males with Duchenne muscular dystrophy. *Dev Med Child Neurol* 2007; **49**: 123-128 [PMID: 17254000 DOI: 10.1111/j.1469-8749.2007.00123.x]

76 **Cyrulnik SE**, Hinton VJ. Duchenne muscular dystrophy: a cerebellar disorder? *Neurosci Biobehav Rev* 2008; **32**: 486-496 [PMID: 18022230 DOI: 10.1016/j.neubiorev.2007.09.001]

77 **Anderson JL**, Head SI, Rae C, Morley JW. Brain function in Duchenne muscular dystrophy. *Brain* 2002; **125**: 4-13 [PMID: 11834588 DOI: 10.1093/brain/awf012]

78 **Daoud F**, Angeard N, Demerre B, Martie I, Benyaou R, Leturcq F, Cossée M, Deburgrave N, Saillour Y, Tuffery S, Urtizberea A, Toutain A, Echenne B, Frischman M, Mayer M, Desguerre I, Estournet B, Réveillère C, Penisson-Besnier JM, Kaplan JC, Héron D, Rivier F, Chelly J. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. *Hum Mol Genet* 2009; **18**: 3779-3794 [PMID: 19602481 DOI: 10.1093/hmg/ddp320]

79 **Guan X**, Mack DL, Moreno CM, Strande JL, Mathieu J, Shi Y, Markert CD, Wang Z, Liu G, Lawlor MW, Moorefield EC, Jones TN, Fugate JA, Furth ME, Murry CE, Ruohola-Baker H, Zhang Y, Santana LF, Childers MK. Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. *Stem Cell Res* 2014; **12**: 467-480 [PMID: 24434629 DOI: 10.1016/j.scr.2013.12.004]

80 **Luo Y**, Fan Y, Chen X, Yue L, Yu B, Li Q, Chen Y, Sun X. Modeling induced pluripotent stem cells from fibroblasts of Duchenne muscular dystrophy patients. *Int J Neurosci* 2014; **124**: 12-21 [PMID: 23528047 DOI: 10.3109/00207454.2013.789514]

81 **Lin B**, Li Y, Han L, Kaplan AD, Ao Y, Kalra S, Bett GC, Rasmusson RL, Denning C, Yang L. Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. *Dis Model Mech* 2015; **8**: 457-466 [PMID: 25791035 DOI: 10.1242/dmm.019505]

82 **Li HL**, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Reports* 2015; **4**: 143-154 [PMID: 25434822 DOI: 10.1016/j.stemcr.2014.10.013]

83 **Kazuki Y**, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C, Takehara S, Higaki K, Nakagawa M, Takahashi K, Yamanaka S, Oshimura M. Complete genetic correction of ips cells from Duchenne muscular dystrophy. *Mol Ther* 2010; **18**: 386-393 [PMID: 19997091 DOI: 10.1038/mt.2009.274]

84 **Ousterout DG**, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. *Nat Commun* 2015; **6**: 6244 [PMID: 25692716 DOI: 10.1038/ncomms7244]

85 **Abrahams BS**, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. *Nat Rev Genet* 2008; **9**: 341-355 [PMID: 18414403 DOI: 10.1038/nrg2346]

86 **Quaak I**, Brouns MR, Van de Bor M. The dynamics of autism spectrum disorders: how neurotoxic compounds and neurotransmitters interact. *Int J Environ Res Public Health* 2013; **10**: 3384-3408 [PMID: 23924882 DOI: 10.3390/ijerph10083384]

87 **Acab A**, Muotri AR. The Use of Induced Pluripotent Stem Cell Technology to Advance Autism Research and Treatment. *Neurotherapeutics* 2015; **12**: 534-545 [PMID: 25851569]

88 **Paşca SP**, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A, Paşca AM, Cord B, Palmer TD, Chikahisa S, Nishino S, Bernstein JA, Hallmayer J, Geschwind DH, Dolmetsch RE. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. *Nat Med* 2011; **17**: 1657-1662 [PMID: 22120178 DOI: 10.1038/nm.2576]

89 **Urbach A**, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. *Cell Stem Cell* 2010; **6**: 407-411 [PMID: 20452313 DOI: 10.1016/j.stem.2010.04.005]

90 **Martins-Taylor K**, Hsiao JS, Chen PF, Glatt-Deeley H, De Smith AJ, Blakemore AI, Lalande M, Chamberlain SJ. Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi syndrome patient with an atypical deletion. *Hum Mol Genet* 2014; **23**: 2364-2373 [PMID: 24363065 DOI: 10.1093/hmg/ddt628]

91 **Sarasua SM**, Dwivedi A, Boccuto L, Chen CF, Sharp JL, Rollins JD, Collins JS, Rogers RC, Phelan K, DuPont BR. 22q13.2q13.32 genomic regions associated with severity of speech delay, developmental delay, and physical features in Phelan-McDermid syndrome. *Genet Med* 2014; **16**: 318-328 [PMID: 24136618 DOI: 10.1038/gim.2013.144]

92 **Splawski I**, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell* 2004; **119**: 19-31 [PMID: 15454078]

93 **Boczek NJ**, Miller EM, Ye D, Nesterenko VV, Tester DJ, Antzelevitch C, Czosek RJ, Ackerman MJ, Ware SM. Novel Timothy syndrome mutation leading to increase in CACNA1C window current. *Heart Rhythm* 2015; **12**: 211-219 [PMID: 25260352 DOI: 10.1016/j.hrthm.2014.09.051]

94 **Bading H**. Nuclear calcium signalling in the regulation of brain function. *Nat Rev Neurosci* 2013; **14**: 593-608 [PMID: 23942469 DOI: 10.1038/nrn3531]

95 **Catterall WA**, Leal K, Nanou E. Calcium channels and short-term synaptic plasticity. *J Biol Chem* 2013; **288**: 10742-10749 [PMID: 23400776 DOI: 10.1074/jbc.R112.411645]

96 **Ebert DH**, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. *Nature* 2013; **493**: 327-337 [PMID: 23325215 DOI: 10.1038/nature11860]

97 **Krey JF**, Paşca SP, Shcheglovitov A, Yazawa M, Schwemberger R, Rasmusson R, Dolmetsch RE. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. *Nat Neurosci* 2013; **16**: 201-209 [PMID: 23313911 DOI: 10.1038/nn.3307]

98 **Yazawa M**, Dolmetsch RE. Modeling Timothy syndrome with iPS cells. *J Cardiovasc Transl Res* 2013; **6**: 1-9 [PMID: 23299782 DOI: 10.1007/s12265-012-9444-x]

99 **Sheridan SD**, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. *PLoS One* 2011; **6**: e26203 [PMID: 22022567 DOI: 10.1371/journal.pone.0026203]

100 **Rogers SJ**, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. *J Dev Behav Pediatr* 2001; **22**: 409-417 [PMID: 11773805 DOI: 10.1097/00004703-200112000-00008]

101 **Kumari D**, Swaroop M, Southall N, Huang W, Zheng W, Usdin K. High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. *Stem Cells Transl Med* 2015; **4**: 800-808 [PMID: 25999519 DOI: 10.5966/sctm.2014-0278]

102 **Bassell GJ**, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. *Neuron* 2008; **60**: 201-214 [PMID: 18957214 DOI: 10.1016/j.neuron.2008.10.004]

103 **Liu J**, Koscielska KA, Cao Z, Hulsizer S, Grace N, Mitchell G, Nacey C, Githinji J, McGee J, Garcia-Arocena D, Hagerman RJ, Nolta J, Pessah IN, Hagerman PJ. Signaling defects in iPSC-derived fragile X premutation neurons. *Hum Mol Genet* 2012; **21**: 3795-3805 [PMID: 22641815 DOI: 10.1093/hmg/dds207]

104 **Doers ME**, Musser MT, Nichol R, Berndt ER, Baker M, Gomez TM, Zhang SC, Abbeduto L, Bhattacharyya A. iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. *Stem Cells Dev* 2014; **23**: 1777-1787 [PMID: 24654675 DOI: 10.1089/scd.2014.0030]

105 **Chamberlain SJ**, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, Lalande M. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. *Proc Natl Acad Sci U S A* 2010; **107**: 17668-17673 [PMID: 20876107 DOI: 10.1073/pnas.1004487107]

106 **Rougeulle C**, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. *Nat Genet* 1997; **17**: 14-15 [PMID: 9288088 DOI: 10.1038/ng0997-14]

107 **Vu TH**, Hoffman AR. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. *Nat Genet* 1997; **17**: 12-13 [PMID: 9288087 DOI: 10.1038/ng0997-12]

108 **Meng L**, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. *Nature* 2015; **518**: 409-412 [PMID: 25470045 DOI: 10.1038/nature13975]

109 **Cassidy SB**, Dykens E, Williams CA. Prader-Willi and Angelman syndromes: sister imprinted disorders. *Am J Med Genet* 2000; **97**: 136-146 [PMID: 11180221 DOI: 10.1002/1096-8628(200022)97:2<136::AID-AJMG5>3.0.CO;2-V]

110 **Germain ND**, Chen PF, Plocik AM, Glatt-Deeley H, Brown J, Fink JJ, Bolduc KA, Robinson TM, Levine ES, Reiter LT, Graveley BR, Lalande M, Chamberlain SJ. Gene expression analysis of human induced pluripotent stem cell-derived neurons carrying copy number variants of chromosome 15q11-q13.1. *Mol Autism* 2014; **5**: 44 [PMID: 25694803 DOI: 10.1186/2040-2392-5-44]

111 **Phelan K**, McDermid HE. The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome). *Mol Syndromol* 2012; **2**: 186-201 [PMID: 22670140]

112 **Kolevzon A**, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. *Mol Autism* 2014; **5**: 54 [PMID: 25685306 DOI: 10.1186/2040-2392-5-54]

113 **Naisbitt S**, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, Worley PF, Sheng M. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. *Neuron* 1999; **23**: 569-582 [PMID: 10433268 DOI: 10.1016/S0896-6273(00)80809-0]

114 **Durand CM**, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet* 2007; **39**: 25-27 [PMID: 17173049 DOI: 10.1038/ng1933]

115 **Phelan MC**. Deletion 22q13.3 syndrome. *Orphanet J Rare Dis* 2008; **3**: 14 [PMID: 18505557 DOI: 10.1186/1750-1172-3-14]

116 **Wang X**, McCoy PA, Rodriguiz RM, Pan Y, Je HS, Roberts AC, Kim CJ, Berrios J, Colvin JS, Bousquet-Moore D, Lorenzo I, Wu G, Weinberg RJ, Ehlers MD, Philpot BD, Beaudet AL, Wetsel WC, Jiang YH. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. *Hum Mol Genet* 2011; **20**: 3093-3108 [PMID: 21558424 DOI: 10.1093/hmg/ddr212]

117 **Shcheglovitov A**, Shcheglovitova O, Yazawa M, Portmann T, Shu R, Sebastiano V, Krawisz A, Froehlich W, Bernstein JA, Hallmayer JF, Dolmetsch RE. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. *Nature* 2013; **503**: 267-271 [PMID: 24132240 DOI: 10.1038/nature12618]

118 **Amir RE**, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999; **23**: 185-188 [PMID: 10508514 DOI: 10.1038/13810]

119 **Chahrour M**, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. *Neuron* 2007; **56**: 422-437 [PMID: 17988628 DOI: 10.1016/j.neuron.2007.10.001]

120 **Percy AK**. Rett syndrome: exploring the autism link. *Arch Neurol* 2011; **68**: 985-989 [PMID: 21825235 DOI: 10.1001/archneurol.2011.149]

121 **Hotta A**, Cheung AY, Farra N, Vijayaragavan K, Séguin CA, Draper JS, Pasceri P, Maksakova IA, Mager DL, Rossant J, Bhatia M, Ellis J. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. *Nat Methods* 2009; **6**: 370-376 [PMID: 19404254 DOI: 10.1038/nmeth.1325]

122 **Cheung AY**, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Hotta A, Carrel L, Ellis J. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. *Hum Mol Genet* 2011; **20**: 2103-2115 [PMID: 21372149 DOI: 10.1093/hmg/ddr093]

123 **Kim KY**, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. *Proc Natl Acad Sci U S A* 2011; **108**: 14169-14174 [PMID: 21807996 DOI: 10.1073/pnas.1018979108]

124 **Farra N**, Zhang WB, Pasceri P, Eubanks JH, Salter MW, Ellis J. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. *Mol Psychiatry* 2012; **17**: 1261-1271 [PMID: 22230884 DOI: 10.1038/mp.2011.180]

125 **Djuric U**, Cheung AY, Zhang W, Mok RS, Lai W, Piekna A, Hendry JA, Ross PJ, Pasceri P, Kim DS, Salter MW, Ellis J. MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells. *Neurobiol Dis* 2015; **76**: 37-45 [PMID: 25644311]

126 **Williams EC**, Zhong X, Mohamed A, Li R, Liu Y, Dong Q, Ananiev GE, Mok JC, Lin BR, Lu J, Chiao C, Cherney R, Li H, Zhang SC, Chang Q. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. *Hum Mol Genet* 2014; **23**: 2968-2980 [PMID: 24419315 DOI: 10.1093/hmg/ddu008]

127 **Baudouin SJ**. [Mouse models of autism: a common basis for syndromic and non syndromic autisms *Med Sci (Paris)* 2013; **29**: 121-123 [PMID: 23452591 DOI: 10.1051/medsci/2013292002]

128 **Griesi-Oliveira K**, Acab A, Gupta AR, Sunaga DY, Chailangkarn T, Nicol X, Nunez Y, Walker MF, Murdoch JD, Sanders SJ, Fernandez TV, Ji W, Lifton RP7, Vadasz E, Dietrich A, Pradhan D, Song H, Ming GL, Gu X, Haddad G, Marchetto MC, Spitzer N, Passos-Bueno MR, State MW, Muotri AR. Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons. *Mol Psychiatry* 2014 Nov 11; Epub ahead of print [PMID: 25385366 DOI: 10.1038/mp.2014.141]

129 **De Rubeis S**, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, Singh T, Klei L, Kosmicki J, Shih-Chen F, Aleksic B, Biscaldi M, Bolton PF, Brownfeld JM, Cai J, Campbell NG, Carracedo A, Chahrour MH, Chiocchetti AG, Coon H, Crawford EL, Curran SR, Dawson G, Duketis E, Fernandez BA, Gallagher L, Geller E, Guter SJ, Hill RS, Ionita-Laza J, Jimenz Gonzalez P, Kilpinen H, Klauck SM, Kolevzon A, Lee I, Lei I, Lei J, Lehtimäki T, Lin CF, Ma'ayan A, Marshall CR, McInnes AL, Neale B, Owen MJ, Ozaki N, Parellada M, Parr JR, Purcell S, Puura K, Rajagopalan D, Rehnström K, Reichenberg A, Sabo A, Sachse M, Sanders SJ, Schafer C, Schulte-Rüther M, Skuse D, Stevens C, Szatmari P, Tammimies K, Valladares O, Voran A, Li-San W, Weiss LA, Willsey AJ, Yu TW, Yuen RK, Cook EH, Freitag CM, Gill M, Hultman CM, Lehner T, Palotie A, Schellenberg GD, Sklar P, State MW, Sutcliffe JS, Walsh CA, Scherer SW, Zwick ME, Barett JC, Cutler DJ, Roeder K, Devlin B, Daly MJ, Buxbaum JD. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 2014; **515**: 209-215 [PMID: 25363760 DOI: 10.1038/nature13772]

130 **Sullivan PF**, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry* 2003; **60**: 1187-1192 [PMID: 14662550]

131 **Brennand KJ**, Gage FH. Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia. *Stem Cells* 2011; **29**: 1915-1922 [PMID: 22009633 DOI: 10.1002/stem.762]

132 **Carpenter WT**, Buchanan RW. Schizophrenia. *N Engl J Med* 1994; **330**: 681-690 [PMID: 8107719]

133 **Cardno AG**, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. *Am J Med Genet* 2000; **97**: 12-17 [PMID: 10813800]

134 **Brown AS**. The environment and susceptibility to schizophrenia. *Prog Neurobiol* 2011; **93**: 23-58 [PMID: 20955757 DOI: 10.1016/j.pneurobio.2010.09.003]

135 **Torrey EF**, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. *Schizophr Bull* 2012; **38**: 642-647 [PMID: 22446566 DOI: 10.1093/schbul/sbs043]

136 **Scherr M**, Hamann M, Schwerthöffer D, Froböse T, Vukovich R, Pitschel-Walz G, Bäuml J. Environmental risk factors and their impact on the age of onset of schizophrenia: Comparing familial to non-familial schizophrenia. *Nord J Psychiatry* 2012; **66**: 107-114 [PMID: 21879797 DOI: 10.3109/08039488.2011.605171]

137 **Connor CM**, Dincer A, Straubhaar J, Galler JR, Houston IB, Akbarian S. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. *Schizophr Res* 2012; **140**: 175-184 [PMID: 22804924 DOI: 10.1016/j.schres.2012.06.037]

138 **Chiang CH**, Su Y, Wen Z, Yoritomo N, Ross CA, Margolis RL, Song H, Ming GL. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. *Mol Psychiatry* 2011; **16**: 358-360 [PMID: 21339753 DOI: 10.1038/mp.2011.13]


139 **Brennand KJ**, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, Li Y, Mu Y, Chen G, Yu D, McCarthy S, Sebat J, Gage FH. Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 2011; **473**: 221-225 [PMID: 21490598 DOI: 10.1038/nature09915]

140 **Bundo M**, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi T, Sunaga F, Toritsuka M, Ikawa D, Kakita A, Kato M, Kasai K, Kishimoto T, Nawa H, Okano H, Yoshikawa T, Kato T, Iwamoto K. Increased l1 retrotransposition in the neuronal genome in schizophrenia. *Neuron* 2014; **81**: 306-313 [PMID: 24389010 DOI: 10.1016/j.neuron.2013.10.053]


141 **Brennand KJ**, Landek-Salgado MA, Sawa A. Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells. *Biol Psychiatry* 2014; **75**: 936-944 [PMID: 24331955 DOI: 10.1016/j.biopsych.2013.10.025]

142 **Hermann A**, Storch A. Induced neural stem cells (iNSCs) in neurodegenerative diseases. *J Neural Transm* 2013; **120** Suppl 1: S19-S25 [PMID: 23720190 DOI: 10.1007/s00702-013-1042-9]

**P-Reviewer:** Gary LD, Kim, YB **S-Editor:** Qiu S **L-Editor: E-Editor:**

****

**Figure 1 Steps for neuronal and glial differentiation protocol.** NPC: Neural progenitor cells.



**Figure 2 Scheme of neurological disease modeling using iPSC technology for future personalized treatments.** NPC: Neural progenitor cells; iPSC: Induced pluripotent stem cell.